{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T03:34:29Z","timestamp":1758944069176,"version":"3.37.3"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Incyte Corporation"},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"crossref","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson MDS\/AML Moon Shot"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.leukres.2018.09.004","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T12:25:54Z","timestamp":1536927954000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7912","authenticated-orcid":false,"given":"Yasmin","family":"Abaza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana E.","family":"Hidalgo-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yesid","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Soltysiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.leukres.2018.09.004_bib0005","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2018.09.004_bib0010","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2018.09.004_bib0015","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2018.09.004_bib0020","first-page":"4265","article-title":"Sequential stratification prognostic score for patients with intermediate-risk myelodysplastic syndrome","volume":"130","author":"Benton","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2018.09.004_bib0025","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2018.09.004_bib0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"31","key":"10.1016\/j.leukres.2018.09.004_bib0035","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1073\/pnas.0811267106","article-title":"A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide","volume":"106","author":"Wei","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.leukres.2018.09.004_bib0040","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.24102","article-title":"Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Garcia-Manero","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2018.09.004_bib0045","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.004_bib0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2018.09.004_bib0055","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2018.09.004_bib0060","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2018.09.004_bib0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2018.09.004_bib0070","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-12-3540","article-title":"Prospective phase II study on 5-days azacitidine for treatment of symptomatic and\/or erythropoietin unresponsive patients with low\/INT-1-risk myelodysplastic syndromes","volume":"19","author":"Fili","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.leukres.2018.09.004_bib0075","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1200\/JCO.2012.44.6823","article-title":"Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes","volume":"31","author":"Garcia-Manero","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2018.09.004_bib0080","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.29145","article-title":"Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS clinical research consortium","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2018.09.004_bib0085","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.3324\/haematol.2012.071050","article-title":"Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure","volume":"98","author":"Prebet","year":"2013","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.leukres.2018.09.004_bib0090","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2018.09.004_bib0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MOH.0000000000000400","article-title":"Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes","volume":"25","author":"Montalban-Bravo","year":"2018","journal-title":"Curr. Opin. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2018.09.004_bib0100","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2015.69","article-title":"Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes","volume":"29","author":"Ganan-Gomez","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2018.09.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071120","article-title":"Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes","volume":"8","author":"Dimicoli","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.leukres.2018.09.004_bib0110","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2018.09.004_bib0115","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2018.09.004_bib0120","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl. J Med."},{"issue":"21","key":"10.1016\/j.leukres.2018.09.004_bib0125","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood.V122.21.3463.3463","article-title":"Ruxolitinib inhibits dendritic cell function by interfering with the MAP-Kinase\/NF-Kb signalling pathways","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.004_bib0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/cr.2010.171","article-title":"Structural studies of NF-kappaB signaling","volume":"21","author":"Zheng","year":"2011","journal-title":"Cell. Res."},{"issue":"9","key":"10.1016\/j.leukres.2018.09.004_bib0135","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cellsig.2010.03.017","article-title":"Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway","volume":"22","author":"Huang","year":"2010","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.leukres.2018.09.004_bib0140","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.004_bib0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","article-title":"Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2018.09.004_bib0150","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ajh.24746","article-title":"An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes","volume":"92","author":"Daher","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2018.09.004_bib0155","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2018.09.004_bib0160","first-page":"1005","article-title":"Nuclear factor k B is activated in myelodysplastic bone marrow cells","volume":"87","author":"Sanz","year":"2002","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2018.09.004_bib0165","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2013.180","article-title":"Toll-like receptor alterations in myelodysplastic syndrome","volume":"27","author":"Wei","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2018.09.004_bib0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yexmp.2010.01.009","article-title":"Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia","volume":"88","author":"Kuninaka","year":"2010","journal-title":"Exp. Mol. Pathol."},{"issue":"4","key":"10.1016\/j.leukres.2018.09.004_bib0175","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/1078-0432.CCR-06-2108","article-title":"Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes","volume":"13","author":"Maratheftis","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.leukres.2018.09.004_bib0180","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3324\/haematol.2012.064642","article-title":"Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production","volume":"98","author":"Velegraki","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.leukres.2018.09.004_bib0185","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/leu.2013.91","article-title":"Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells","volume":"27","author":"Wei","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2018.09.004_bib0190","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.leukres.2018.09.004_bib0195","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2005-04-1424","article-title":"NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)","volume":"106","author":"Kerbauy","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2018.09.004_bib0200","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2005-05-1989","article-title":"NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome","volume":"107","author":"Braun","year":"2006","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.leukres.2018.09.004_bib0205","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1038\/sj.onc.1210187","article-title":"NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"26","author":"Fabre","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.004_bib0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.2054","article-title":"Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype","volume":"16","author":"Starczynowski","year":"2010","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.leukres.2018.09.004_bib0215","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1182\/blood-2010-12-324715","article-title":"Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2018.09.004_bib0220","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin. Cancer Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T02:49:29Z","timestamp":1571885369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618302108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":44,"alternative-id":["S0145212618302108"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.09.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}